02The 2025 semaglutide trial tested short-term behavior A 2025 randomized trial by Hendershot and colleagues tested low-dose semaglutide in 48 non-treatment-seeking adults with alcohol use disorder
Prepare the Pen If using a multi-dose pen, attach a fresh needle
Enjoy a high-protein, healthy-fat, and fibre-filled breakfast to start your day
Renal Outcomes Sixteen studies, including one meta-analysis, reported at least one renal outcome
Whilst beneficial for weight loss and glycaemic control, a substantial caloric deficitparticularly if nutritional intake becomes inadequatemay contribute to fatigue and reduced energy levels
Exenatide Extended-Release (Bydureon BCise) Bydureon BCise received FDA approval on October 20, 2017 offering a once weekly exenatide formulation